Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8734865 | Surgical Pathology Clinics | 2018 | 30 Pages |
Abstract
Ancillary testing in breast cancer has become standard of care to determine what therapies may be most effective for individual patients with breast cancer. Single-marker tests are required on all newly diagnosed and newly metastatic breast cancers. Markers of proliferation are also used, and include both single-marker tests like Ki67 as well as panel-based gene expression tests, which have made more recent contributions to prognostic and predictive testing in breast cancers. This review focuses on pathologist interpretation of these ancillary test results, with a focus on expected versus unexpected results and troubleshooting borderline, unusual, or discordant results.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Kimberly H. MD,